UBS Group’s Actinium Pharmaceuticals ATNM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14.5K | Buy |
14,618
+14,522
| +15,127% | +$17.3K | ﹤0.01% | 8161 |
|
|
2025
Q4 | $131 | Sell |
96
-14,480
| -99% | -$21.1K | ﹤0.01% | 10155 |
|
|
2025
Q3 | $23.3K | Sell |
14,576
-11,014
| -43% | -$17.9K | ﹤0.01% | 8058 |
|
|
2025
Q2 | $35.8K | Sell |
25,590
-370,546
| -94% | -$555K | ﹤0.01% | 8040 |
|
|
2025
Q1 | $638K | Buy |
396,136
+307,320
| +346% | +$390K | ﹤0.01% | 5668 |
|
|
2024
Q4 | $112K | Buy |
88,816
+51,837
| +140% | +$80.4K | ﹤0.01% | 6800 |
|
|
2024
Q3 | $69.5K | Buy |
36,979
+14,205
| +62% | +$56.1K | ﹤0.01% | 6601 |
|
|
2024
Q2 | $169K | Sell |
22,774
-4,942
| -18% | -$40.7K | ﹤0.01% | 5785 |
|
|
2024
Q1 | $217K | Sell |
27,716
-2,041
| -7% | -$13.1K | ﹤0.01% | 5804 |
|
|
2023
Q4 | $151K | Buy |
29,757
+17,594
| +145% | +$90.6K | ﹤0.01% | 5942 |
|
|
2023
Q3 | $72K | Buy |
+12,163
| New | +$80.9K | ﹤0.01% | 6061 |
|
|
2023
Q2 | – | Sell |
-2,704
| Closed | -$25.6K | – | 8891 |
|
|
2023
Q1 | $25.6K | Sell |
2,704
-531
| -16% | -$5.61K | ﹤0.01% | 6906 |
|
|
2022
Q4 | $34.5K | Buy |
3,235
+1,399
| +76% | +$14.2K | ﹤0.01% | 7101 |
|
|
2022
Q3 | $13K | Buy |
1,836
+1,800
| +5,000% | +$11.2K | ﹤0.01% | 8005 |
|
|
2022
Q2 | $0 | Buy |
+36
| New | +$204 | ﹤0.01% | 10291 |
|
|
2022
Q1 | – | Sell |
-50
| Closed | – | – | 10223 |
|
|
2021
Q4 | $0 | Sell |
50
-100
| -67% | -$750 | ﹤0.01% | 10237 |
|
|
2021
Q3 | $1K | Sell |
150
-2,693
| -95% | -$18.7K | ﹤0.01% | 9136 |
|
|
2021
Q2 | $22K | Buy |
2,843
+2,693
| +1,795% | +$21.1K | ﹤0.01% | 7224 |
|
|
2021
Q1 | $1K | Buy |
+150
| New | +$1.27K | ﹤0.01% | 8746 |
|
|
2020
Q3 | – | Sell |
-2,437
| Closed | -$26K | – | 7963 |
|
|
2020
Q2 | $26K | Sell |
2,437
-1,924
| -44% | -$14.6K | ﹤0.01% | 6367 |
|
|
2020
Q1 | $25K | Sell |
4,361
-1,472
| -25% | -$10.5K | ﹤0.01% | 6344 |
|
|
2019
Q4 | $38K | Buy |
5,833
+3,178
| +120% | +$21.9K | ﹤0.01% | 6509 |
|
|
2019
Q3 | $18K | Sell |
2,655
-689
| -21% | -$4.8K | ﹤0.01% | 6791 |
|
|
2019
Q2 | $25K | Buy |
3,344
+3,063
| +1,090% | +$30.8K | ﹤0.01% | 6459 |
|
|
2019
Q1 | $4K | Sell |
281
-1,070
| -79% | -$17.1K | ﹤0.01% | 7245 |
|
|
2018
Q4 | $16K | Buy |
+1,351
| New | +$23K | ﹤0.01% | 6933 |
|
|
2018
Q2 | – | Sell |
-114
| Closed | -$1K | – | 7965 |
|
|
2018
Q1 | $1K | Sell |
114
-5,289
| -98% | -$89.9K | ﹤0.01% | 7623 |
|
|
2017
Q4 | $108K | Buy |
+5,403
| New | +$109K | ﹤0.01% | 5298 |
|
|
2017
Q2 | – | Sell |
-435
| Closed | -$20K | – | 7646 |
|
|
2017
Q1 | $20K | Buy |
435
+308
| +243% | +$11.8K | ﹤0.01% | 6133 |
|
|
2016
Q4 | $3K | Buy |
+127
| New | +$3.97K | ﹤0.01% | 7395 |
|
|
2016
Q3 | – | Sell |
-172
| Closed | -$9K | – | 7656 |
|
|
2016
Q2 | $9K | Buy |
+172
| New | +$9.6K | ﹤0.01% | 6828 |
|
|
2015
Q3 | – | Sell |
-13
| Closed | -$1K | – | 8396 |
|
|
2015
Q2 | $1K | Sell |
13
-32
| -71% | -$2.73K | ﹤0.01% | 8307 |
|
|
2015
Q1 | $3K | Sell |
45
-2
| -4% | -$238 | ﹤0.01% | 8310 |
|
|
2014
Q4 | $8K | Buy |
+47
| New | +$8.93K | ﹤0.01% | 8563 |
|
Other funds holding ATNM
VCM
GS
VFT
UBS Group's ATNM Position: Q1 2026 in Review
UBS Group increased its Actinium Pharmaceuticals (ATNM) stake by 15,127% in Q1 2026, buying an estimated $17.3K and bringing the position to 14,618 shares worth $14.5K. The position accounts for ﹤0.01% of the portfolio, ranked #8161.
UBS Group first reported a position in ATNM in Q4 2014 and has held it in 34 quarters since. The position peaked at $638K in Q1 2025. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.
- UBS Group held 14,618 shares of Actinium Pharmaceuticals worth $14.5K as of Q1 2026.
- UBS Group bought 14,522 Actinium Pharmaceuticals shares in Q1 2026, an estimated $17.3K.
- Actinium Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8161 holding.
- UBS Group first reported a position in Actinium Pharmaceuticals in Q4 2014 and has held it in 34 quarters since.
- UBS Group's Actinium Pharmaceuticals position peaked at $638K in Q1 2025.
- 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.